KarMMa-RW: comparison of idecabtagene vicleucel with realworld outcomes in relapsed and refractory multiple myeloma

Patients with relapsed and refractory multiple myeloma (RRMM) who are triple-class exposed (to an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody) have limited treatment options and there is no standard of care. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cel...

Descripción completa

Detalles Bibliográficos
Autores: Jagannath, S. (Sundar)|||/items/4ddac83b-b2bb-48c0-8c50-a3345d7785d1, Lin, H.Y. (H.Y.)|||/items/b9b8f67b-6528-43e3-a1b8-fcdea818cbb7, Goldschmidt, H. (Hartmut)|||/items/6ace6bbb-2456-4c9c-8cfc-bc473ff26341, Reece, D. (Donna)|||/items/dd5750cb-2721-46f7-9af4-c0895d4a9530, Nooka, A. (Ajay)|||/items/b564d027-4050-4370-957a-ddac1eb2964e, Senin, M.A. (María Alicia)|||/items/519a4e82-f80d-45c1-adac-fcafcd63ba94, Rodriguez-Otero, P. (Paula)|||/items/bb21b679-c3ea-4d5a-9939-f330219406c8, Powles, R. (Ray)|||/items/bd545399-faff-4d68-9add-c2fa08e601dd, Matsue, K. (Kosei)|||/items/1aae20d8-243b-4095-84bc-fbb959203a50, Shah, N. (Nina)|||/items/789f2c08-5c96-4021-a173-d1f1a84d1889, Anderson Jr, L.D. (Larry D.)|||/items/58dbcbfe-8a2e-4162-9111-ac3a73c8a385, Streetly, M. (Matthew)|||/items/e4a12926-11be-4d3b-96cd-8e52e858d73e, Wilson, K. (Kimberly)|||/items/61a046e2-bfb7-487d-b5b3-cf4e81b5022a, Le, H.V. (Hoa Van)|||/items/806063b1-12d3-4bca-b9e7-2b9725f9e7ac, Swern, A.S. (Arlene S.)|||/items/36e10477-7419-408f-b71b-f29a7bc329d1, Agarwal, A. (Amit)|||/items/8ee8c0f8-b38c-4bb6-9f78-9b7647ffbaca, Siegel, D.S. (David S.)|||/items/5413a196-70bb-4075-ad3c-3ffee07ffc5d
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/114768
Acceso en línea:https://hdl.handle.net/10171/114768
Access Level:acceso abierto
Palabra clave:Multiple myeloma
Idecabtagene vicleucel
KarMMa trial
Descripción
Sumario:Patients with relapsed and refractory multiple myeloma (RRMM) who are triple-class exposed (to an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody) have limited treatment options and there is no standard of care. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, demonstrated efficacy in triple-class exposed RRMM patients in the KarMMa trial (NCT03361748). In this retrospective study (KarMMa-RW), patient-level data from triple-class exposed RRMM patients were merged into a single data model and compared with KarMMa using trimmed stabilized inverse probability of treatment weighting. Endpoints included overall response rate (ORR; primary), rate of very good partial response or better (≥VGPR), progression-free survival (PFS), and overall survival (OS). Of 1949 real-world triple-class exposed RRMM patients, 190 received subsequent (index) line of therapy and met KarMMa eligibility criteria (Eligible RRMM cohort). With a median follow-up of 13.3 months in KarMMa and 10.2 months in Eligible RRMM, ORR, and ≥VGPR were significantly improved in KarMMa versus Eligible RRMM (ORR, 76.4% vs 32.2%; ≥VGPR, 57.9% vs 13.7%; both P < 0.0001) as were PFS (11.6 vs 3.5 months; P = 0.0004) and OS (20.2 vs 14.7 months; P = 0.0006). This study demonstrated that ide-cel significantly improved responses and survival compared with currently available therapies in triple-class exposed RRMM.

Similares en LA Referencia